CONCLUSION
toxicity, SCLC
SCLC
Antiangiogenic therapy (apatinib) plus chemotherapy had encouraging efficacy. Also, no intolerable toxicity was observed for this new regimen, which should provide an insight into the current status of second‐line therapy in SCLC.